<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322149</url>
  </required_header>
  <id_info>
    <org_study_id>AT-1501-A201</org_study_id>
    <nct_id>NCT04322149</nct_id>
  </id_info>
  <brief_title>Multiple Doses of AT-1501-A201 in Adults With ALS</brief_title>
  <official_title>A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anelixis Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eledon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized&#xD;
      monoclonal antibody antagonist to CD40L. Approximately 54 adults with ALS will be enrolled&#xD;
      into the study in the United States and Canada at approximately 13 ALS treatment sites.&#xD;
&#xD;
      Participants will be enrolled into one of four ascending doses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized&#xD;
      monoclonal antibody antagonist to CD40L. Approximately 54 adults with ALS will be enrolled&#xD;
      into the study in the United States and Canada at approximately 13 ALS treatment sites.&#xD;
&#xD;
      Four ascending doses of AT-1501 will be administered as an IV infusion to sequentially&#xD;
      enrolling cohorts. Each participant will receive 6 bi-weekly (every other week) infusions of&#xD;
      AT-1501 over an 11-week period.&#xD;
&#xD;
      The study is estimated to take 19 weeks for participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Approx. 5 Months</time_frame>
    <description>Incidence of adverse events (AEs) as characterized by changes in physical examination, vital signs, ECG, laboratory parameters, and C-SSRS</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>AT-1501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 sequential dose cohorts</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-1501</intervention_name>
    <description>AT-1501 monoclonal antibody targeting CD40L given as an IV infusion</description>
    <arm_group_label>AT-1501</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ALS diagnosed as possible, laboratory supported probable, probable, or definite as&#xD;
             defined by revised El Escorial criteria&#xD;
&#xD;
          2. ALSFRS-R Aggregate score of 37 or greater&#xD;
&#xD;
          3. No more than 24 months from diagnosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other central or peripheral nervous system disease that may interfere with the&#xD;
             evaluation of ALS or its progression&#xD;
&#xD;
          2. Presence of a tracheostomy, or use of permanent assistive ventilation (ventilatory&#xD;
             support for 23 hours per day or more)&#xD;
&#xD;
          3. History of malignancy within the previous 5 years, except for localized non-melanoma&#xD;
             skin cancers&#xD;
&#xD;
          4. Abnormal function of the immune system resulting from:&#xD;
&#xD;
               -  Clinical conditions affecting the immune system (e.g. HIV infection,&#xD;
                  agammaglobulinemia),&#xD;
&#xD;
               -  Systemic administration of corticosteroids (PO/IV/IM) at a dose equivalent to 20&#xD;
                  mg/day of prednisone for more than 14 consecutive days within 90 days prior to&#xD;
                  screening,&#xD;
&#xD;
               -  Administration of anti-neoplastic and/or immunomodulating agents (e.g. TNF Î±&#xD;
                  antagonists or anti-B cell antibodies) or radiotherapy within 1 year prior to&#xD;
                  screening.&#xD;
&#xD;
          5. Recipient of Stem Cell or Gene Therapy&#xD;
&#xD;
          6. Positive test for Hepatitis B surface antigen, Hepatitis C antibody, or HIV.&#xD;
&#xD;
          7. History of deep venous thrombosis or pulmonary embolism&#xD;
&#xD;
          8. History of active substance abuse within the past 2 years&#xD;
&#xD;
          9. History of stroke, poorly controlled or significant cardiovascular disease, diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Bornstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Eledon Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Bartoshevich</last_name>
    <phone>949-238-8090</phone>
    <email>clinicaltrials@eledon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barrows Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Study Staff</last_name>
      <phone>602-406-4232</phone>
      <email>stephanie.Strong@dignityhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Staff</last_name>
      <phone>714-509-2661</phone>
      <email>eonv@hs.uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Staff</last_name>
      <phone>415-600-3758</phone>
      <email>EngelM@cpmcri.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Staff</last_name>
      <phone>706-721-2681</phone>
      <email>BQUARLES@augusta.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Staff</last_name>
      <phone>317-963-7382</phone>
      <email>sguingri@iu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Study Staff</last_name>
      <phone>913-945-9922</phone>
      <email>ksims2@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Staff</last_name>
      <phone>410-955-8511</phone>
      <email>kriley15@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Study Staff</last_name>
      <phone>617-643-4803</phone>
      <email>ZSCHEIER@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery (HSS)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Study Staff</last_name>
      <phone>646-797-8592</phone>
      <email>HolzbergS@hss.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Brain &amp; Spine Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Study Staff</last_name>
      <phone>503-962-1171</phone>
      <email>arlena.cummings@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Neurology, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Study Staff</last_name>
      <phone>214-827-3610</phone>
      <email>kgallegos@texasneurology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Study Staff</last_name>
      <phone>713-441-9120</phone>
      <email>rgapplegate@houstonmethodist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Lou Gehirg's Disease</keyword>
  <keyword>motor neuron disease</keyword>
  <keyword>motor neuron degeneration</keyword>
  <keyword>AT-1501</keyword>
  <keyword>humanized blocking antibody to CD40LG</keyword>
  <keyword>CD40L inhibitor</keyword>
  <keyword>monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

